new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Immunomedics Inc patents


      
Recent patent applications related to Immunomedics Inc. Immunomedics Inc is listed as an Agent/Assignee. Note: Immunomedics Inc may have other listings under different names/spellings. We're not affiliated with Immunomedics Inc, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics Inc-related inventors




Search recent Press Releases: Immunomedics Inc-related press releases
Count Application # Date Immunomedics Inc patents (updated weekly) - BOOKMARK this page
12016003200302/04/16  new patent  Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
22016003200402/04/16  new patent  Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
32016003200802/04/16  new patent  Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
42016002421201/28/16 Humanized anti-hla-dr antibodies
52016000091501/07/16 Crosslinking of cd22 by epratuzumab triggers bcr signaling and caspase-dependent apoptosis in hematopoietic cancer cells
62015036698812/24/15 Antibody-drug conjugates and uses thereof
72015036836212/24/15 Anti-histone therapy for vascular necrosis in severe glomerulonephritis
82015034308712/03/15 Class i anti-cea antibodies and uses thereof
92015034457312/03/15 Humanized anti-cd22 antibody
102015032087211/12/15 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
112015031528911/05/15 Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2)
122015030624310/29/15 Antibody-sn-38 immunoconjugates with a cl2a linker
132015030624410/29/15 Anthracycline-antibody conjugates for cancer therapy
142015030752410/29/15 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
152015028326410/08/15 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
162015025211009/10/15 Anti-cd19 antibodies
172015023997408/27/15 Humanized rfb4 anti-cd22 antibody
182015022419208/13/15 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
192015021699708/06/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
202015021700608/06/15 Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
212015020231907/23/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
222015020232007/23/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
232015019665307/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
242015019665407/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
252015019666107/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
262015019666207/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
272015019666407/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
282015019666507/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
292015019666607/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
302015018263307/02/15 Immunoconjugates with an intracellularly-cleavable linkage
312015018388007/02/15 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
322015017426906/25/15 Immunoconjugates with an intracellularly-cleavable linkage
332015017427006/25/15 Immunoconjugates with an intracellularly-cleavable linkage
342015016507506/18/15 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
352015016507606/18/15 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
362015016665906/18/15 Humanized l243 antibodies
372015016666906/18/15 Anti-cd74 immunoconjugates and methods of use
382015015096906/04/15 Chimeric and humanized anti-histone antibodies
392015013276805/14/15 Anti-pancreatic cancer antibodies
402015012538605/07/15 Humanized anti-ceacam5 antibody and uses thereof
412015011127904/23/15 Class i anti-cea antibodies and uses thereof
422015009445604/02/15 Anthracycline-antibody conjugates for cancer therapy
432015008648203/26/15 Dye conjugated peptides for fluorescent imaging
442015005743202/26/15 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
452015003868602/05/15 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
462015001851601/15/15 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
472014037717312/25/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
482014037717712/25/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
492014037728712/25/14 Anti-trop-2 antibody-drug conjugates and uses thereof
502014036992712/18/14 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
512014028686009/25/14 Immunoconjugates with an intracellularly-cleavable linkage
522014028686109/25/14 Rs7 antibodies
532014023420908/21/14 Chimeric and humanized anti-histone antibodies
542014022717808/14/14 Humanized anti-hla-dr antibodies
552014022717908/14/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
562014022718008/14/14 Antibody-sn-38 immunoconjugates with a cl2a linker
572014022854108/14/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
582014021991408/07/14 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
592014021995608/07/14 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
602014021242507/31/14 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
612014019335907/10/14 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
622014017829406/26/14 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
632014017006506/19/14 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
642014015427306/05/14 Anthracycline-antibody conjugates for cancer therapy
652014014738205/29/14 Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
662014014092405/22/14 Humanized l243 antibodies
672014012003505/01/14 Rs7 antibodies
682014011286404/24/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
692014011286504/24/14 Anti-cd19 antibodies
702014010581904/17/14 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
712014009925804/10/14 Camptothecin-binding moiety conjugates
722014008683003/27/14 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
732014008683203/27/14 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
742014007962903/20/14 Class i anti-cea antibodies and uses thereof
752014005806702/27/14 Immunoconjugates with an intracellularly-cleavable linkage
762014004463902/13/14 Antibody therapy
772014004464002/13/14 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
782014003754302/06/14 Anti-pancreatic cancer antibodies
792014003826102/06/14 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
802014003828402/06/14 Mammalian cell lines for increasing longevity and protein yield from a cell culture
812014001716801/16/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
822014001719701/16/14 Anti-cd19 antibodies
832014000407801/02/14 Immunoconjugates with an intracellularly-cleavable linkage
842013031582111/28/13 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
852013030917711/21/13 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
862013021656108/22/13 Immunoconjugates with an intracellularly-cleavable linkage
872013020935608/15/13 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
882013021104408/15/13 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
892013017749807/11/13 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
902013017752607/11/13 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
912013017106407/04/13 Anti-cd74 immunoconjugates and methods of use
922013017106507/04/13 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
932013017117607/04/13 Anthracycline-antibody conjugates for cancer therapy
942013016421406/27/13 Antibody-based depletion of antigen-presenting cells and dendritic cells
952013016478306/27/13 Mammalian cell lines for increasing longevity and protein yield from a cell culture
962013015669106/20/13 Antibody therapy
972013014278706/06/13 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
982013014329606/06/13 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
992013012191305/16/13 Anti-cd19 antibodies
1002013012347305/16/13 Bispecific antibody targeting a complement factor or complement regulatory protein
1012013009503404/18/13 Anti-cd74 immunoconjugates and methods
1022013009045804/11/13 Immunoconjugates with an intracellularly-cleavable linkage
1032013007818203/28/13 Structural variants of antibodies for improved therapeutic characteristics
1042013007826303/28/13 Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
1052013007132003/21/13 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1062013007140603/21/13 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
1072013007265903/21/13 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1082013003986102/14/13 Dye conjugated peptides for fluorescent imaging
1092013003449202/07/13 Class i anti-cea antibodies and uses thereof
1102012032856412/27/12 Camptothecin-binding moiety conjugates
1112012032863412/27/12 Immunoconjugates with an intracellularly-cleavable linkage
1122012032155312/20/12 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
1132012028217811/08/12 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1142012027610011/01/12 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1152012023095309/13/12 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
1162012021496908/23/12 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1172012019632608/02/12 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1182012018954207/26/12 Anti-cd19 antibodies
1192012018347207/19/12 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1202012018355007/19/12 Therapeutic using a bispecific antibody
1212012014908506/14/12 Fusion proteins containing recombinant cytotoxic rnases
1222012014137206/07/12 Rs7 antibodies
1232012014137506/07/12 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
1242012013492005/31/12 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1252012011455605/10/12 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1262012010723505/03/12 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1272012008829904/12/12 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1282012008261704/05/12 Immunoconjugates with an intracellularly-cleavable linkage
1292012007672703/29/12 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
1302012006399303/15/12 Therapeutic and diagnostic conjugates for use with multispecific antibodies
1312012003979702/16/12 Antibody therapy
1322012004043102/16/12 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1332012003418502/09/12 Anti-cd20 antibodies and fusion proteins therof and methods of use
1342011031153112/22/11 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1352011030563112/15/11 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
1362011030006612/08/11 Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
1372011029351312/01/11 Immunoconjugates with an intracellularly-cleavable linkage
1382011028691811/24/11 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1392011028080111/17/11 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1402011027470411/10/11 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1412011025605310/20/11 Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
1422011024384110/06/11 Antibody-based depletion of antigen-presenting cells and dendritic cells
1432011024454610/06/11 Internalizing anti-cd74 antibodies and methods of use
1442011023630409/29/11 Structural variants of antibodies for improved therapeutic characteristics
1452011023640409/29/11 Methods for protein expression in mammalian cells in serum-free medium
1462011022940709/22/11 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1472011022364509/15/11 Multivalent carriers of bi-specific antibodies
1482011019502308/11/11 Internalizing anti-cd74 antibodies and methods of use
1492011018908508/04/11 Antibody therapy
1502011018926808/04/11 Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1512011017112607/14/11 Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1522011016507207/07/11 Detection of early-stage pancreatic adenocarcinoma
1532011016507307/07/11 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1542011011701005/19/11 Methods and compositions for administering therapeutic and diagnostic agents
1552011011710505/19/11 Method of treating immune disease using b-cell antibodies
1562011011085405/12/11 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1572011007623303/31/11 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1582011007015503/24/11 Anti-cd74 immunoconjugates and methods
1592011007015603/24/11 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1602011006465303/17/11 Class i anti-cea antibodies and uses thereof
1612011005248903/03/11 Anti-cd19 antibodies
1622010031116212/09/10 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1632010028490611/11/10 Internalizing anti-cd74 antibodies and methods of use
1642010027263610/28/10 Anti-cd74 immunoconjugates and methods of use
1652010026649610/21/10 Anti-cd74 immunoconjugates and methods of use
1662010026649710/21/10 Internalizing anti-cd74 antibodies and methods of use
1672010023377909/16/10 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1682010022688409/09/10 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1692010022117509/02/10 Antibody therapy
1702010022117709/02/10 Rs7 antibodies
1712010021666208/26/10 Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1722010020296108/12/10 D-amino acid peptides
1732010019626608/05/10 Humanized anti-hla-dr antibodies
1742010019626708/05/10 Humanized l243 antibodies
1752010019698908/05/10 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1762010018964107/29/10 Novel strategies for improved cancer vaccines
1772010015880206/24/10 Chimeric, human and humanized anti-csap monoclonal antibodies
1782010015880306/24/10 Production and use of novel peptide-based agents for use with bi-specific antibodies
1792010013662606/03/10 Production and use of novel peptide-based agents for use with bi-specific antibodies
1802010010458904/29/10 Immunoconjugates with an intracellularly-cleavable linkage
1812010007484003/25/10 Anthracycline-antibody conjugates for cancer therapy
1822010006813603/18/10 Anti-cd19 antibodies
1832010004054102/18/10 Structural variants of antibodies for improved therapeutic characteristics
1842010003473802/11/10 Structural variants of antibodies for improved therapeutic characteristics
1852010001504601/21/10 Camptothecin-binding moiety conjugates
1862010001504801/21/10 Internalizing anti-cd74 antibodies and methods of use
1872010000885501/14/10 Production and use of novel peptide-based agents with bispecific antibodies
1882010000885801/14/10 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1892009030458012/10/09 Anti-pancreatic cancer antibodies
1902009029903312/03/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1912009029109311/26/09 Immunoconjugates with an intracellularly-cleavable linkage
1922009028575211/19/09 Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
1932009027464911/05/09 Bispecific antibody point mutations for enhancing rate of clearance
1942009025273110/08/09 Multivalent carriers of bi-specific antibodies
1952009025317910/08/09 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1962009024613010/01/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1972009024613110/01/09 Production and use of novel peptide-based agents for use with bi-specific antibodies
1982009024621410/01/09 Fusion proteins containing recombinant cytotoxic rnases
1992009023875709/24/09 Methods and compositions for administering therapeutic and diagnostic agents
2002009024003709/24/09 Humanized antibodies and methods of humanizing antibodies
2012009018597407/23/09 Chimeric, human and humanized anti-granulocyte antibodies and methods of use
2022009015516606/18/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
2032009015525306/18/09 Anti-cd20 antibodies and fusion proteins therof and methods of use
2042009011114304/30/09 Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
2052009009259804/09/09 Antibody therapy
2062010001504801/21/10 Internalizing anti-cd74 antibodies and methods of use
2072010000885801/14/10 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###